Please login to the form below

Not currently logged in
Email:
Password:

RNA interference

This page shows the latest RNA interference news and features for those working in and with pharma, biotech and healthcare.

NICE says no to rival Alnylam and Akcea amyliodsis drugs – but deal could be done

NICE says no to rival Alnylam and Akcea amyliodsis drugs – but deal could be done

Gaining NICE recommendation would be a major milestone for both companies – Onpattro is Alnylam’s debut product from its RNA interference (RNAi) drug platform, while Tegsedi is similarly Akcea’s first ... product from its antisense drug technology,

Latest news

  • Moderna files record $500m IPO for RNA pipeline Moderna files record $500m IPO for RNA pipeline

    Could be the largest IPO for a biotech start-up. Moderna Therapeutics, a specialist in messenger RNA-based drugs, has filed a $500m initial public offering (IPO) that would break all ... It’s a different spin on other RNA approaches, such as RNA

  • Alnylam gets EU nod for Onpattro amid pricing backlash Alnylam gets EU nod for Onpattro amid pricing backlash

    The  EMA has cleared Onpattro (patisiran) – the first RNA interference drug approved in the EU – for adult hATTR amyloidosis patients with stage 1 or 2 nerve damage (polyneuropathy), one of the

  • ICER says Alnylam’s Onpattro should cost 90%-95% less ICER says Alnylam’s Onpattro should cost 90%-95% less

    In draft guidance, the Institute for Clinical and Economic Review (ICER) says that RNA interference drug Onpattro (patisiran) – and Akcea/Ionis’ antisense candidate Tegsedi (inotersen) which is due for an FDA

  • Alnylam claims RNAi milestone with Onpattro approval Alnylam claims RNAi milestone with Onpattro approval

    After years of ups and downs, triumph for gene-silencing tech. Alnylam’s faith in the gene-silencing potential of RNA interference (RNAi) drugs has finally paid off, with the US ... RNAi drugs are used to block gene expression, binding to the messenger

  • Alnylam’s amyloidosis drug heads latest crop of CHMP approvals Alnylam’s amyloidosis drug heads latest crop of CHMP approvals

    The green light sets up the first product approval for Alnylam, an RNA interference specialist which has been working on gene-silencing drugs for around 15 years and is also due ... RNA process that results in TTR protein expression.

More from news
Approximately 1 fully matching, plus 29 partially matching documents found.

Latest appointments

  • Silence appoints chief medical officer Silence appoints chief medical officer

    These studies involve Silence's investigational portfolio of RNA interference (RNAi) therapeutics, which aim to treat conditions by selectively turning off genes expressed in an individual with a certain disease.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics